|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||7.05 - 7.05|
|52 Week Range||6.70 - 12.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep 21, 2017 - Sep 22, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
LONDON, UK / ACCESSWIRE / April 23, 2018 / With the refocusing of the business and the new CEO's strategic review now implemented, e-Therapeutics (LSE: ETX) finds itself with the NDD platform and at least ...
LONDON, UK / ACCESSWIRE / January 5. 2018 / e-Therapeutics' (LSE: ETX) Network-Driven Drug Discovery (NDD) platform has begun to deliver encouraging data that should support out-licensing of its immuno-oncology ...
e-Therapeutics plc (AIM:ETX), a GBP£24.83M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronicRead More...
e-Therapeutics plc (AIM:ETX), a biotechnology company based in United Kingdom, received a lot of attention from a substantial price movement on the AIM in the over the last few months,Read More...
e-Therapeutics plc (AIM:ETX), a pharmaceuticals, biotechnology and life sciences company based in United Kingdom, received a lot of attention from a substantial price movement on the AIM in the overRead More...
e-Therapeutics plc : Upon the completion of Ray Barlow’s first three months as CEO of e-Therapeutics, the Company outlines below the conclusion of the strategic review for its investors and other stakeholders.